Cancer Conversations Blog

March 20, 2013

Should men with prostate cancer receive DEXA screening?

By: Mary B. Daly, MD, PhD, FACP

Prostate cancer is the most common cancer among men in the United States and the second leading cause of cancer death.  The use of androgen-deprivation therapy (ADT), which reduce male hormone levels, or prevent them from reaching the prostate cancer cells, prolongs  survival and improves quality of life, and is used in close to 50 percent of all men with prostate cancer.

March 18, 2013

The Love Rx

By: Karen Mechanic, MD

In February, Fox Chase Cancer Center marked the third anniversary of Love Versus Cancer – a campaign designed to honor and promote the strength and hope that love brings to the challenge of confronting cancer.

March 8, 2013

Trends in Smoking Related Deaths

By: Mary B. Daly, MD, PhD, FACP

New data from the U.S. National Health Interview Survey confirm the health hazards of smoking. Mortality from any cause among smokers, both men and women, is three times higher than non-smokers.

March 7, 2013

Patient and Family-Centered Care at Fox Chase

By: David Cohen

Patient- and family-centered care is an approach to the planning, delivery and evaluation of health care that is grounded in mutually beneficial partnerships among health care providers, patients and families. It redefines the relationships in health care.

March 7, 2013

Is Active Surveillance Safe for Small Renal Masses?

By: Marc C. Smaldone, MD

With more frequent use of abdominal imaging, such as CT scan or MRI, the number of people diagnosed with small asymptomatic kidney tumors is rising rapidly.

March 5, 2013

Breast Cancer Can Also Affect Men

By: Richard J. Bleicher, MD, FACS

Although we typically think of women when we think of breast cancer, approximately 2,000 men per year are diagnosed with the disease.

February 26, 2013

FDA Approves New Drug for Breast Cancer

By: Lori J. Goldstein, MD, FASCO

Kadcyla, also referred to as T-DM1, is a new drug that was approved by the Food and Drug Administration (FDA) on February 22, 2013, intended for patients who were previously treated with trastuzumab (also known as Herceptin), another anti-HER2 therapy, and taxanes, a class of chemotherapy drugs commonly used for the treatment of breast cancer. (Read full article in the New York Times).

February 13, 2013

What are the Options for Breast Reconstruction Using Tissue from the Abdominal Wall?

By: Neal S. Topham, MD, FACS

Women seeking options for breast reconstruction for mastectomy should be offered the option of using tissue from the abdominal wall for unilateral or bilateral breast reconstruction. For patients desiring a more natural reconstruction, with the best cosmetic appearance and texture, the abdomen is a very good option.